Biological warfare and the skin I: Bacteria and toxins

Clinics in Dermatology

Volumn 20, Issue 4, 2002, Pages 346-354

  Cieslak, Theodore J ^a,b   Talbot, Thomas B ^a   Hartstein, Bonnie H ^a  

^a San Antonio Military Pediatric Center   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTITOXIN; BOTULINUM TOXIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; MYCOTOXIN; PENICILLIN G; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE DERIVATIVE; TRICHOTHECENE DERIVATIVE; VANCOMYCIN; VIRULENCE FACTOR;

ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; BIOLOGICAL WARFARE; BOTULISM; BURKHOLDERIA PSEUDOMALLEI; CLINICAL FEATURE; CLOSTRIDIUM BOTULINUM; DISEASE CLASSIFICATION; DISEASE COURSE; FRANCISELLA TULARENSIS; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; INFECTION PREVENTION; MELIOIDOSIS; MORTALITY; MYCOTOXICOSIS; NONHUMAN; PLAGUE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SANITATION; SKIN; TULAREMIA; YERSINIA PESTIS;

ANTHRAX; BIOLOGICAL WARFARE; BOTULISM; HUMANS; MELIOIDOSIS; PLAGUE; SKIN DISEASES; TRICHOTHECENES; TULAREMIA;

EID: 0036657921     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00254-7     Document Type: Article

References (32)

1. Centers for Disease Control. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR. 50:2001;941-948.
2. Jernigan J.A., Stephens D.S., Ashford D.A., et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerging Infect Dis. 7:2001;933-944.
3. Cieslak T.J., Rowe J.R., Kortepeter M.G., et al. A field-expedient algorithmic approach to the clinical management of chemical and biological casualties. Milit Med. 165:2000;659-662.
4. Cieslak T.J., Eitzen E.M. Bioterrorism: agents of concern. J Public Health Manage Pract. 6:2000;19-29.
5. Khan A.S., Morse S., Lillibridge S. Public-health preparedness for biological terrorism in the USA. Lancet. 356:2000;1179-1182.
6. Dirckx J.H. Virgil on anthrax. Am J Dermatopathol. 3:1981;191-195.
7. Dixon T.C., Meselson M., Guillemin J., Hanna P.C. Anthrax. N Engl J Med. 341:1999;815-825.
8. Kohout E., Sehat A., Ashraf M. Anthrax: a continuous problem in south west Iran. Am J Med Sci. 247:1964;565.
9. Turner M. Anthrax in humans in Zimbabwe. Centr Afr J Med. 26:1980;160-161.
10. Krishna-Rao N.S.K., Mohiyudeen S. Tabanus flies as transmitters of anthrax: a field experience. Indian Vet J. 35:1958;348-353.
11. Mallon E., McKee P.H. Extraordinary case report: cutaneous anthrax. Am J Dermatopathol. 19:1997;79-82.
12. Christopher G.W., Cieslak T.J., Pavlin J.A., Eitzen E.M. Biological warfare: a historical perspective. JAMA. 278:1997;412-417.
13. Meselson M., Guillemin J., High-Jones M., et al. The Sverdlovsk anthrax outbreak of 1979. Science. 266:1994;1202-1208.
14. Centers for Disease Control. Update: investigation of bioterrorism-related anthrax. Connecticut, 2001. MMWR. 50:2001;1077-1079.
15. Centers for Disease Control. Considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR. 50:2001;984-986.
16. Inglesby T.V., Henderson D.A., Bartlett J.G., et al. Anthrax as a biological weapon: medical and public health management. JAMA. 281:1999;1735-1745.
17. Centers for Disease Control. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR. 50:2001;909-919.
18. Derbes V.J. DeMussis and the great plague of 1348. JAMA. 196:1966;179-182.
19. McGovern T.W., Friedlander A.M. Plague. Zajtchuk R. Textbook of military medicine: medical aspects of chemical and biological warfare. 1997;479-502 Borden Institute, US Army Washington, DC.
20. Inglesby T.V., Dennis D.T., Henderson D.A., et al. Plague as a biological weapon: medical and public health management. JAMA. 283:2000;2281-2290.
21. Franz D.R., Jahrling P.B., McClain D.J., et al. Clinical recognition and management of patients exposed to biological warfare agents. Clin Lab Med. 21:2001;435-473.
22. Alibek K. Biohazard: the chilling true story of the largest covert biological weapons program in the world, told from the inside by the man who ran it. 1999;29-38 Random House New York.
23. Centers for Disease Control. Summary of notifiable diseases, United States, 1997. MMWR. 46:1998;71-80.
24. Evans M.E., Gregory D.W., Schaffner W., McGee Z.A. Tularemia: a 30-year experience with 88 cases. Medicine. 64:1985;251-269.
25. Penn R.L. Francisella tularensis (tularemia). Mandell G.L. Bennett J.E. Dolin R. Principles and practice of infectious diseases. 4th ed. 1995;2060-2068 Churchill-Livingston New York.
26. Dennis D.T., Inglesby T.V., Henderson D.A., et al. Tularemia as a biological weapon, medical and public health management. JAMA. 285:2001;2763-2773.
27. Cieslak T.J., Christopher G.W., Kortepeter M.G., et al. Immunization against potential biological warfare agents. Clin Infect Dis. 30:2000;843-850.
28. 2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis. 23:1996;337-340.
29. McGovern T.W., Christopher G.W., Eitzen E.M. Cutaneous manifestations of biological warfare and related threat agents. Arch Dermatol. 135:1999;311-322.
30. Franz D.R. Defense against toxin weapons. 1997;21 US Army Medical Research and Materiel Command Ft Detrick, MD.
31. Centers for Disease Control. Update: pulmonary hemorrhage/hemosiderosis among infants: Cleveland, Ohio, 1993-1996. MMWR. 49:2000;180-184.
32. Hagmann M. A mold's toxic legacy revisited. Science. 288:2000;243-244.